Charles River Laboratories stock (US1591881009): Shares dip after recent run-up as analysts eye upside potential

Charles River Laboratories stock has pulled back after a strong monthly gain, even as analysts highlight upside potential and the company continues to post solid quarterly revenue.

Shares of Charles River Laboratories have retreated from recent highs, with the stock trading around 187.93 USD on the New York Stock Exchange on May 9, 2026, down about 3.76% over the past 24 hours after a 30.48% rise over the prior month, according to TradingView data as of May 9, 2026.

Despite the short?term pullback, the stock remains up roughly 1.47% over the last year, reflecting continued investor interest in the preclinical and clinical services provider as it navigates a competitive life?sciences outsourcing landscape, according to TradingView as of May 9, 2026.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Charles River Laboratories International, Inc.
• Sector/industry: Life sciences, contract research and laboratory services
• Headquarters/country: United States
• Core markets: Pharmaceutical, biotechnology, medical device companies worldwide
• Key revenue drivers: Preclinical and clinical laboratory services, research models, and manufacturing support
• Home exchange/listing venue: NYSE (ticker: CRL)
• Trading currency: USD

Charles River Laboratories: core business model

Charles River Laboratories provides non?clinical drug development services, research models, and manufacturing support to pharmaceutical, biotechnology, and medical device companies, positioning itself as a key outsourcing partner in the early stages of drug discovery and development, according to StockStory as of May 9, 2026.

The company’s portfolio spans discovery and safety assessment, laboratory animal supply and related services, and biopharmaceutical testing and manufacturing support, allowing clients to outsource complex preclinical and clinical?stage work while maintaining regulatory compliance, according to TradingView as of May 9, 2026.

This integrated model gives Charles River Laboratories exposure to global drug development pipelines, with revenue linked to the volume and complexity of outsourced studies and the number of research models supplied to life?sciences firms, according to StockStory as of May 9, 2026.

Main revenue and product drivers for Charles River Laboratories

Recent quarterly data show that Charles River Laboratories generated about 1.03 billion USD in revenue for the latest quarter, slightly above the estimated 985.24 million USD, according to TradingView as of May 9, 2026.

Net income for that quarter reached approximately 52.33 million USD, up sharply from about 25.47 million USD in the prior quarter, reflecting a year?over?year increase of more than 100%, according to TradingView as of May 9, 2026.

Earlier reporting for the fourth quarter of 2025 indicated revenue of 994.2 million USD, roughly flat year on year but 1.4% above analyst expectations, with non?GAAP earnings of 2.39 USD per share, about 1.9% above consensus, according to StockStory as of May 9, 2026.

Organic revenue in that period declined 2.6% year on year, suggesting that growth is being supported by acquisitions and pricing rather than underlying volume expansion, according to StockStory as of May 9, 2026.

Analysts expect revenue of about 990.82 million USD in the next quarter, implying modest sequential growth and continued pressure on margins if organic demand remains soft, according to TradingView as of May 9, 2026.

Why Charles River Laboratories matters for US investors

For US investors, Charles River Laboratories offers exposure to the broader biopharma outsourcing trend, where large pharmaceutical and biotech firms increasingly rely on specialized contract research organizations to manage preclinical and clinical work, according to StockStory as of May 9, 2026.

The company’s listing on the NYSE in USD makes it accessible to retail and institutional investors without currency?conversion hurdles, while its diversified service lines help insulate it somewhat from downturns in any single therapeutic area, according to TradingView as of May 9, 2026.

With a market capitalization of about 9.61 billion USD as of early May 2026, Charles River Laboratories sits in the mid?cap segment of the healthcare services sector, offering a balance between growth potential and relative stability compared with smaller, more speculative biotech names, according to TradingView as of May 9, 2026.

Conclusion

Charles River Laboratories stock has recently pulled back after a strong monthly advance, even as the company continues to post solid quarterly revenue and earnings that are broadly in line with or slightly above market expectations, according to TradingView and StockStory as of May 9, 2026.

Analysts see upside potential, with one?year price targets averaging around 199.07 USD and a range from about 160.00 USD to 211.00 USD, implying moderate to high upside from current levels, according to StockStory and TradingView as of May 9, 2026.

However, organic revenue trends remain under pressure, and the stock’s valuation, with a forward price?to?earnings ratio near 14.9 times, leaves limited room for disappointment, underscoring the importance of monitoring future order intake, margin performance, and integration of any acquisitions, according to StockStory as of May 9, 2026.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.